NASDAQ:RVMD Revolution Medicines Q3 2025 Earnings Report $48.75 0.00 (0.00%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Revolution Medicines EPS ResultsActual EPSN/AConsensus EPS -$1.39Beat/MissN/AOne Year Ago EPSN/ARevolution Medicines Revenue ResultsActual RevenueN/AExpected Revenue$1.81 millionBeat/MissN/AYoY Revenue GrowthN/ARevolution Medicines Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Revolution Medicines Earnings HeadlinesDid Leadership Moves Just Shift Revolution Medicines' (RVMD) Investment Narrative Ahead of Key Launches?October 7, 2025 | finance.yahoo.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives $74.64 Consensus Price Target from AnalystsOctober 7, 2025 | americanbankingnews.comDARPA Set to Trigger New Boom: Buy These 3 StocksBy the end of this month, DARPA — the government agency that invented the internet — is expected to make a major quantum computing announcement that could send three little-known quantum stocks soaring.October 14 at 2:00 AM | Brownstone Research (Ad)Revolution Medicines, Inc. (RVMD) Insider Sells SharesOctober 2, 2025 | insidermonkey.comRevolution Medicines Shows Improved Relative Strength; Still Shy Of BenchmarkSeptember 30, 2025 | msn.comRevolution Medicines, Inc.: Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development OfficerSeptember 29, 2025 | finanznachrichten.deSee More Revolution Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Revolution Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revolution Medicines and other key companies, straight to your email. Email Address About Revolution MedicinesRevolution Medicines (NASDAQ:RVMD) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance. The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations. These candidates are being evaluated in various phases of clinical development across solid tumors, with the goal of delivering first-in-class or best-in-class therapies for patients with limited treatment options. Founded in 2015 and headquartered in Redwood City, California, Revolution Medicines operates research facilities in North America and collaborates with academic institutions and industry partners to accelerate innovation. The management team comprises experienced executives with deep expertise in oncology drug discovery, guiding the company’s strategic partnerships and clinical advancement efforts.View Revolution Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025)Kinder Morgan (10/15/2025)Morgan Stanley (10/15/2025)Progressive (10/15/2025)Prologis (10/15/2025)The PNC Financial Services Group (10/15/2025)CSX (10/16/2025)Interactive Brokers Group (10/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
